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Abstract
Background: Globally there are few reports of the impairments, disabilities and medications used in people living
with idiopathic Parkinson’s disease. Caregiver characteristics and caregiver burden have seldom been reported. We
examined the health status in a large cohort of people living with Parkinson’s disease and their caregivers managed
in a comprehensive health care setting.
Methods/Design: A prospective, cross sectional analysis of impairments, disabilities and Parkinson’s disease
medication use was conducted in a sample of 100 people with Parkinson’s disease rated I-IV on the modified Hoehn
& Yahr scale. Participants were recruited from the Victorian Comprehensive Parkinson Program in Melbourne,
Australia. Their caregivers were invited to provide their views on the burden of care, services provided and support
received.
Results: The severity of impairments and disabilities was strongly associated with disease duration (mean of 5.5
years). Those with long standing disease or more severe disease also used more Parkinson’s disease medications
and participated in fewer social roles than people who were newly diagnosed or mildly affected. The severity of
impairments was strongly correlated with limitations in performing activities of daily living. Limitations in performing
daily activities were also found to be a significant contributing factor for health-related quality of life (PDQ-39 SI
β=0.55, p=0.000; EQ-5D SI β=0.43, p=0.001). People with Parkinson’s disease lived at home with relatives. The
average caregiver was a spouse or child providing approximately 3.5 hours of care per day, with the capacity to
provide 9.4 hours per day and had provided care for four years. Additional support was high (63%) for 2.5 hours per
day.
Conclusion: The comprehensive care setting of this cohort describes a relatively benign condition despite a wide
range of disease duration and severity. This report provides a baseline with which to compare other delivery models.
Keywords: Parkinson disease; Australia; Comprehensive care
Introduction
Parkinson disease (PD) is a degenerative and progressive disorder
that mainly affects older people [1]. The rapid population ageing
throughout developed countries means that the number of people
diagnosed with PD will increase to over 10 million by 2050 [2]. Elderly
people have an additional disease debt that accompanies the legacy of
advanced age, making people with PD very prone to complications
such as falls, pneumonia and psychosis, adding to the already high
social and economic burden of the disease [3].
The symptoms of Parkinson’s disease are significant. Parkinson’s
disease affects the size and speed of automatic sequential movements
such as walking, standing, moving from one position to another,
manipulating objects with dexterity, speaking and swallowing [4]. It
also affects automatic control of cognition, mood and behaviour [5].
Dysfunction is associated with difficulty with instrumental activities of
daily living (ADL) such as driving and self-care. Eventually the disease
can involve other brain areas that control bowel, bladder, blood
pressure, sleep and cognition [6].
Although no cure currently exists, treatment is available for the
symptoms of PD, particularly for movement disorders. These benefits
diminish over the longer term and unwanted fluctuations develop [7].
For these reasons, an inter-professional team approach has been
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advocated for the management of the complex array of disorders of
movement, cognition and autonomic function [8,9]. The aim is often
to limit the rate and level of disease progression and to enable people
with PD and others in their lives to enjoy the highest possible quality
of life.
Little information is available that describes the average person with
Parkinson, taking into consideration the effects of duration of disease
and its increasing morbidity. Typically cohorts of patients are
described according to a specific intervention with the focus on the
outcome of that intervention. No studies have described the status of
patients under normal care, but particularly in relation to different
care models and across a range of settings.
This paper describes a cohort of patients referred to the Victorian
Comprehensive Parkinson Program (VCPP). It provides a snapshot of
health, impairments, activity limitations, health-related quality of life
(HRQOL) and caregiver requirements when referred to the Program,
and as such provides a baseline for future outcome measures. It
provides very basic information, which is unfortunately commonly
forgotten in the quest for novel interventions, but nevertheless is
important to provide a normal perspective of the impact of
Parkinson’s disease.
Methods
Recruitment to this study was based on a convenience sample of
newly referred people with PD to the VCPP in Melbourne, Australia
and their caregivers. This included referrals from a large geographical
area comprising metropolitan Melbourne, regional and rural Victoria
and Tasmania in Australia (80 separate postcodes). To be included,
participants were required to have a diagnosis of idiopathic PD
confirmed by a neurologist and be willing and able to give informed
consent. When a person with PD had cognitive impairment (Mini-
mental State Examination (MMSE) [10] <24/30), caregiver consent for
participation was required. Additional consent for access to Medicare
Australia claims data was requested, yet not mandatory. People were
excluded if they were severely disabled [11] (Stage V), had little to no
English language skills, or if they had co-existing neurological,
musculoskeletal or cardiopulmonary conditions that produced
significant motor or cognitive impairments that prevented them from
being tested. The study was approved by the Monash Health Human
Research Ethics Committee (HREC Number 06107B) and the Monash
University Standing Committee on Ethics in Research Involving
Humans (SCERH No. 2006/728MCC) of Australia.
All patients who were referred to the principal investigator (RI)
were considered for participation based on their eligibility to meet the
inclusion criteria. The demographics of the participating cohort
revealed that the age distribution, sex ratio, duration of disease and
severity (as rated according to the modified H&Y Scale) were similar
to published prevalence studies [12,13] and incorporated the broad
extent of the PD timeline and its associated severity ratings. Overall
the cohort can be considered to be a representative sample of the
condition in the Australian context.
After informed consent was received, the baseline measurements
were obtained [14]. These are listed in Table 1 with the maximum
score for each test. A registered physiotherapist or medical practitioner
performed the measurements in the home setting, at the Kingston
Centre Movement Disorders Clinic or at a local clinic. Participants
were also requested to complete a medication diary over two
consecutive days immediately after the visit. Participants with
cognitive impairment were assisted by their caregiver to answer the
questionnaires and complete their medication diaries.
Clinical Measures Variable Maximum Score
Hoehn & Yahr Scale (H&Y) Disease
severity
5*
United Parkinson’s Rating Scale (UPDRS)
Section I (Mentation, behaviour and mood)
Section II (Activities of Daily Living)
Section III (Motor Skills)
Section IV (Complications of therapy)
Disability 16*
43*
56*
23*
Schwab & England (%) Disability 100
Modified Dyskinesia Rating Scale Dyskinesia 4*
Parkinson’s Disease Questionnaire (PDQ39) HRQOL 100*
EUROQOL-5D-3L (EQ-5D-3L) HRQOL 1
EUROQOL Visual Analogue Scale (EQ VAS) HRQOL 100
6m walking test (secs) Mobility *
Timed Up & Go (TUG) (secs) Mobility *
Parkinson Disease Fatigue Scale (PFS) Fatigue 100
Geriatric Depression Scale Depression 15*
Neuro-psychiatric inventory
Severity
Distress
Caregiver
burden
36*
60*
Motor fluctuation diary for previous 24-48
hours
Fluctuations N/A
HRQOL-Health-related quality of life.
*The maximum score/time indicates the most severe impairment.
Table 1: Clinical measures assessed and the corresponding variable.
A caregiver interview was conducted by an experienced general
practitioner and was performed face-to-face with the caregiver only.
The interview focussed on three main areas; the amount and level of
care needed by the help recipient, support services used by the care
recipient and economic information on such things as employment,
informal and formal assistance and government allowances. A total of
24 questions regarding the care needs of the recipient were recorded
on a scale of 1-4 (1=requires no assistance, 4=requires a lot of
assistance). The questions were categorised into personal ADL,
domestic ADL, community engagement, cognitive related assistance
and social support.
Summary statistics including number of participants, mean,
standard deviation (SD), median and range were calculated for all
continuous variables. When subgroup analysis was undertaken 95%
confidence intervals around the mean are reported. Univariate and
multivariate regression analyses were performed to explore the
relationships between impairments, activity limitations and HRQOL.
The dependent outcome variables were overall HRQOL as measured
by the Parkinson’s Disease Questionnaire-39 summary index
(PDQ-39SI) and EuroQoL summary index (EQ-5DSI). Independent
variables included in the analyses were disease severity as measured by
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the modified H&Y scale, disease duration, activity limitations as
measured by the Unified Parkinson’s Disease Rating Scale (UPDRS)
Activities of Daily Living (ADL), depression as measured by the
Geriatric Depression Scale (GDS), fatigue as measured by the
Parkinson Disease Fatigue Scale (PFS), neuropsychiatric symptom
severity as measured by the Neuropsychiatric Inventory (NPI) scale
and cognitive impairment as measured by the MMSE. Disease severity
was classified as mild (stages ≤ 2) and moderate severity (Stages ≥ 2.5)
given the ordinal nature of the modified H&Y scale [15]. All other
variables were treated as continuous variables. An initial evaluation of
the assumptions of the regression analyses led to a powered
transformation of the dependent variables (PDQ39SI and EQ-5DSI) to
improve the normality and linearity of residuals. Disease duration,
activity limitations, depression, cognitive impairment and
neuropsychiatric symptom severity were also transformed to further
reduce skewness and the number of outliers.
Univariate and multivariate regression analyses were also
performed to examine whether the type of caregiver contributed to the
HRQOL of care recipients. Independent variables included in this set
of analyses were disease severity as measured by the modified H&Y
scale, living situation and carer type (partner, family member or
friend). All analyses were conducted using SPSS v20.0 (SPSS Inc,
Chicago, IL).
Variable Community Supported Care
Mean (St Dev) Range Mean (St Dev) Range
Sex frequency* M/F 57/36 - 4/3 -
Age (years) 69.2 (9.7) 43-89 73.1 (5.6) 64-83
BMI (kg/m2) 26.1 (5.4) 16.6-52.8 24.3 (2.2) 21.8-28.2
PD duration (years) 5.8 (5.2) 0-21 9.5 (6.0) 0-20
Severity (H&Y Stage)a
Stage 1 (%)
Stage 1.5 (%)
Stage 2 (%)
Stage 2.5 (%)
Stage 3 (%)
Stage 4 (%)
2.3 (0.9)
22
2
15
26
19
10
1-4 3.1 (1.1)
1
0
0
1
2
2
1-4
MMSE (Score) 27.5 (3.5) 12-30 24.3 (5.7) 14-30
Co-morbities (count) 4.8 (2.5) 0-12 4.9 (1.1) 3-6
Fatigue (ordinal score) 45.7 (13.2) 17-74 49.2 (12.4) 33-66
Depression (score) 4.4 (3.7) 0-14 5.8 (2.6) 3-9
Neuro-psychiatric inventory of caregiver
burden (count)
3.0 (2.6)b 0-11 4.5 (3.3)c 0-8
St Dev: Standard deviation; M: male; F: female; PD: Parkinson’s disease; H&Y: Hoehn and Yahr scale; MMSE: Mini mental state examination.
aMean, standard deviation and range presented for modified Hoehn and Yahr stage followed by percentage of patients at each stage.
bFive participants did not have a caregiver.
cOne participant did not have a caregiver.
*Means and standard deviation reported unless stated otherwise.
Table 2: Population demographics.
Results
Demographic characteristics
The first consecutive 198 people referred to the VCPP over a 22-
month period were considered for the study. Forty-eight people did
not meet the inclusion criteria and were not invited to participate. Of
the remaining 150, 100 were willing and eligible to be in the trial.
Reasons for non-enrolment included disinterest (50%), time
commitment (22%), person felt they were too unwell (16%), or
emotional distress (10%).
Most of this Australian sample were married (67%) and 93% of
participants lived in the community either on their own (16%) or with
others (including spouse/partner, child, friend). The remaining 7%
lived in supported care; hostel or nursing home. Further detailed
analysis of data by setting was not feasible due to the small participant
numbers living in supported care. The demographic and PD
information of the participating cohort are summarised in Table 2.
Fourteen participants had a MMSE score less than 24, which is
consistent with dementia. To some degree this was also reflected
within the UPDRS [16] cognition and behaviour score with a mean
value of 2.8 (SD2.4) and a range of 0-10. The NPI Caregiver Burden
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[17] revealed that 14 participants did not have any neuropsychiatric
disturbances and that the remainder experienced up to 11
neuropsychiatric disturbances (maximum possible on the
questionnaire). The most frequent types of disturbance related to
mood change, apathy, appetite change, agitation, irritability, anxiety,
depression and night time behaviours. Depression was not reported
for most participants, with only 14 reports of depression. The most
common co-morbidities were musculoskeletal (69%), cardiovascular
(50%), gastrointestinal (35%) renal or genito-urinary (32%), allergies
(33%) and psychiatric (30%).
Profile of impairments, activity limitations and health-
related quality of life in Australians with PD
Table 3 summarises the motor impairments, activity limitations and
HRQOL of the participants. Eighty-nine of the participants with PD
were able to complete the 6 metre walk without assistance or assistive
devices, suggesting most people in this sample had only relatively mild
gait impairments. Ninety-one people with PD were able to complete
the Timed “Up & Go” Test (TUG) [18]. The mean value of 11.8
seconds (SD 5.8, range 5.6-40.2) is within the normal range for older
people reported by Morris and colleagues [19] of 7.03-12.66 seconds.
There were a small number of outliers who performed this sequential
motor task very slowly. The motor sub-component of the UPDRS
(Section III) also indicated that the sample as a whole was
comparatively mildly disabled.
The ability to perform ADL was also mildly or moderately
compromised for most people, as seen by the UPDRS ADL and
Schwab & England (S&E) [20] ADL scores in Table 3. Assistance was
required for activities such as showering (36% of participants required
assistance with this at least some of the time), dressing (55%), toileting
(20%), eating (34%), getting in or out of bed or a chair (41%) and
moving about the home (36%). On the S&E ADL instrument 52
participants were rated as independent with or without some slowness
or difficulty with tasks (S&E score at least 80%), 33 participants not
completely independent (S&E score 50-80%) and 15 participants very
dependent (S&E score 20-40%).
Relationships between impairments, activity limitations and
HRQOL in Australians living with PD
Figure 1 demonstrates the relationship between scores on the
modified H&Y and performance on the 6m walk test and the TUG.
This shows that movement slowness was related to disease severity,
with those who were modified H&Y stage III or higher much more
impaired in performing timed gait tests.
For the non-motor impairments, there were moderately strong
relationships. Fatigue was common in the cohort with the PFS [21]
scores highly correlated with longer duration of PD (PFS Score 1:
r=0.321, p<0.01, PFS Score 2: r=0.357, p<0.001) and more severe
disease as measured on the modified H&Y scale (PFS Score 1: r=0.505,
p<0.001, PFS Score 2: r=0.499, p<0.001). Fatigue was also correlated
with low MMSE scores (PFS Score 1: r=-0.343, p<0.001, PFS Score 2:
r=-0.354, p<0.001). There were statistically significant correlations
between scores on PFS and the GDS [22] (PFS Score 1: r=0.653,
p<0.001, PFS Score 2: r=0.644, p<0.000). There were also moderately
strong correlations between the UPDRS cognition scores and the
UPDRS mentation scores (PFS Score 1: r=0.562, p<0.000, PFS Score 2:
r=0.559, p<0.001). No statistically significant relationships were found
between the MMSE score and the neuropsychiatric inventory total
score or the MMSE and the neuropsychiatric inventory depression
score.
Measure Minimum Maximum Mean St Dev
6m Walk Test (secs)a 3.8 17.4 6.6 2.7
6m Walk Test (steps) 26 12.2 3.4
TUGT (secs)b 5.6 40.2 11.8 5.8
Motor Section UPDRS 1 49 21.4 10.8
ADL Section UPDRS 2 35 12.7 7.1
PDQ39 SI 0.8 72.3 25.2 18.0
Schwab and England
(%)
20 100 71.6 22.7
Euroqol-5D SI -0.24 1.00 0.617 0.26
EQ VAS 0.09 1.00 0.609 0.20
St Dev: standard deviation; TUGT: Timed up and go test; UPDRS: United
Parkinson Disease Rating Scale; ADL: Activities of Daily Living; PDQ39 SI:
Parkinson’s Disease Questionnaire Summary Index; EQ VAS: Euroqol Visual
Analogue Scale.
aEleven participants used a gait aid to complete the 6 m Walk Test.
bNine participants used a gait aid to complete the TUGT.
Table 3: Motor impairments, activity limitations and health-related
quality of life measures.
Figure 1: Relationship between disease severity and performance on
the 6m walk test and the TUG.
Health-related quality of life measures also demonstrated the wide
range within the cohort on both the PDQ39SI, the EQ-5D SI (based on
UK population-based values from Dolan [23]) and the Euroqol Visual
Analogue Scales (EQ VAS) [24]. The mean PDQ-39 SI score for this
cohort of Australians living with PD was 25.3 (SD 18.0). Univariate
regression analyses showed that disease severity, activity limitations,
neuropsychiatric symptom severity, depression and fatigue were
significant contributing factors (Table 4). In the multivariate model,
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however, only activity limitations (β=0.55; p=0.000), depression
(β=0.25; p=0.003) and fatigue (β=0.18; p=0.028) appeared to be
significant contributing factors. This model accounted for 74% of the
variance in HRQOL as measured by the PDQ-39SI, with activity
limitations explaining 30% of the variability in disease-specific
HRQOL.
Three participants reported health states that were valued at or
below 0 on the EQ-5D SI. Univariate regression analyses identified
disease severity, activity limitations, neuropsychiatric symptom
severity, depression and fatigue to be significant predictive factors for
generic HRQOL as measured by the EQ-5D SI. However, only activity
limitations (β=0.43; p=0.001) and cognitive impairment (β=-0.23;
p=0.010) remained significant contributing factors in the multivariate
model. This model accounted for 45% of the variance in EQ-5D SI
scores, with activity limitations explaining 18% and cognitive
impairment explaining 5% of the variability respectively.
Medication profiles
The medication profile of the participants with PD is summarised
in Table 5. The eleven participants not on Levodopa, were recently
diagnosed, with a mean H&Y stage of 1.5, and minimal reduction in
HRQOL (PDQ39 SI of <10). The small number of participants taking
dopamine agonists reflected the VCPP philosophy of predominant
Levodopa use and reserving the use of dopamine agonists for
management of dyskinesia. The mean Levodopa equivalent dose was
756.4mg; however, there was a graded increase in the mean dose when
subcategories of disease duration were examined. The mean dose
increased to a mean maximum of 1124.9 mg in advanced disease
compared to a mean dose of 486.3mg at disease onset.
PDQ-39 SI EQ-5D SI
Univariate Multivariate1 Univariate Multivariate1
β 95% CI R2 β 95% CI R2 β 95% CI R2 β 95% CI R2
Disease severity 0.58 1.55, 2.84 33 0.06 -0.56, 0.60 0 0.40 0.03, 0.09 16 -0.03 -0.04, 0.03 0
Activity limitation 0.82 1.25, 1.68 67 0.55 0.68, 1.30 30 0.61 0.03, 0.06 37 0.43 0.13, 0.05 18
PD duration 0.08 -0.05, 0.13 0 0.08 -0.02, 0.09 1 0.08 -0.00, 0.01 1 0.14 -0.00, 0.01 2
Neuropsychiatric
symptom severity
0.34 0.20, 0.82 12 0.06 -0.10, 0.26 0 0.23 0.00, 0.03 5 0.04 -0.01, 0.01 0
Depression 0.69 2.94, 4.73 48 0.25 0.49, 2.26 6 0.52 0.08, 0.16 27 0.14 -0.02, 0.09 2
Fatigue 0.67 0.07, 1.12 45 0.18 0.00, 0.05 3 0.54 0.00, 0.00 29 0.21 0.00, 0.00 4
Cognitive impairment 0.05 -0.83, 1.31 0 0.01 -0.58, 0.63 0 -0.17 -0.08, 0.01 3 -0.23 -0.08, -0.01 5
R2, unique contribution of each predictor variable to the variance in HRQOL in %.
1Enter method p<0.05.
Table 4: Univariate and multivariate regression analyses of factors associated with aspects of HRQOL as measured by the PDQ-39 SI and EQ-5D
SI.
Medication Frequencies (%)
No PD medications 11
Levodopa only 59
Combination therapya 30
Psychotropic Medication 49
Antidepressant Medication 20
aLevodopa+COMT inhibitor.
Table 5: Medication profile of Participants.
The participants not taking the tranquillizer agent quetiapine were
more likely to have more normal cognition (MMSE>25), have mild
disease (modified H&Y 1.5) and low PDQ-39 cognition score (10).
The participants taking antidepressant medications had a higher mean
GDS score (7.7) compared to participants not taking antidepressant
medications (3.7). The movement diary indicated 65% of participants
were consistently mobile, with 18% experiencing period of slowing of
mobility. Abnormal involuntary movements such as tremor and
dyskinesia were reported by only 17% of participants.
Social context, caregiver profile and caregiver burden
Table 6 summarises the caregiver profile and burden of care.
External service supports were limited in the majority of the cohort,
with the major support relating to domestic assistance (54%). This was
provided predominantly by private arrangement (26%) and to a lesser
degree by support organisations (20%). Meal provision was the second
most common support service provided (14%). This was equally
provided by family friends (6%) and support organisations (6%). The
majority of participants did not require any other external assistance.
Univariate regression analysis identified that disease severity (β=0.40;
p=0.000) and partners who were caregivers (β=0.23; p=0.028) were
significant predictors for generic HRQOL as measured by the EQ-5D
SI. In the multivariate model, however, only disease severity appeared
to be the significant contributing factor (β=0.39; p=0.000) explaining
15% of the variance in EQ-5D SI scores.
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Characteristic Frequency
Sex (male) (%) 30
Relationship to recipient
Spouse (%)
Child (%)
60
19
Age (mean (SD), years) 60.3 (14.5)
Main language English (%) 81
Living with recipient of care (%) 70
Continuing to work (%) 30
Change in income due to caregiver role (%) 32
Receiving social benefits (%) 47
Average time in role (years) 4
Average number of hours of care by caregiver
Per day (hours)
Further available hours (hours)
3.5
9.4
Average additional family assistance (hours) 2.5 for 63% of recipients
*Six participants did not have a caregiver. Results presented for 94 participants
only.
Table 6: Caregiver profile*.
Discussion
This cohort study documents the profile of impairments, activity
limitations, HRQOL, medication usage and care requirements of
people living with Parkinson’s disease referred to a service offering a
comprehensive care model. This large cohort of people with PD were
mostly living at home, with a relative, and were troubled by the effects
of co-morbidities as reflected by the predominance of the older age
group. Most were on Levodopa or other PD medications, with overall
good control of mobility with minimal dyskinesias. Cognition was
intact in most individuals in this sample, with minimal evidence of
depression or neuropsychiatric complaints. The majority of
participants were independent in ADL and although HRQOL was
impaired, life quality was relatively high compared to other
international published studies [25,26].
This relatively high HRQOL, compared to other publications, as
well as the high level of community living with minimal disruption to
family life paints a different profile to that which is commonly
promulgated by the pathology and impairment literature [27-30].
Despite this, HRQOL was found to be associated with disease severity,
limitations in performing ADL, depression and fatigue. This concurs
with the findings of Soh et al. [31] and highlights the need to take these
factors into consideration in order to minimise the functional
consequences of PD. Strong relationships were also observed between
motor impairments and activity limitations, confirming the findings
by Tan et al [30]. This provides further supportive evidence that
screening for impairments including postural instability, gait
hypokinesia and freezing may help to optimise functional outcomes.
Finally, and not surprisingly, medication requirements increased
according to disease progression. The impact of this increasing
dependence on medication over time on the life quality and ability of
the person with PD to perform ADL warrants further investigation.
Although the type of caregiver was not found to be a significant
contributor to HRQOL, it was found that if care was provided by the
partner, generic HRQOL was likely to better than when care was
provided by a family member or friend. Programs to assist and
promote the role of the carer with respite provisions have been
recognised to be important aspects of the comprehensive care model
[32]. Sustaining the HRQOL of the caregiver is no less important than
for the person with PD and would benefit from further study to
understand the needs of the caregiver in the provision of their role, in
particular the age, gender and health status of the caregiver.
In this study, in-depth analyses of individuals with PD living in
community support facilities were not feasible due to the limited
number of participants recruited (7%). It is important to note,
however, that participants in this sample who lived in care facilities
were more severely impaired, and the caregiver burden was higher. A
larger sample characterising PD patients across a variety of settings
including residential care is therefore warranted. It may also be useful
to include measures of wellbeing in future investigations in order to
determine how these individuals may be satisfied with their personal
life and social situation [33,34].
The main limitation of this study was that participants were limited
to individuals with mild to moderate disease. Given that individuals
with advanced disease (H&Y Stage 5) were not included in the sample,
these findings may not necessarily be generalised to this subgroup.
Whilst further work is required to examine the profile of a broader
sample of people living with PD, this study has provided a snapshot of
the health status of a cohort of individuals with PD and their
caregivers. This information forms a foundation on which future
studies can compare the efficacy of different models of care on people
living with this debilitating condition.
To conclude, this report provides a representative snapshot,
including caregiver role, of a diverse group of people with PD across a
wide domicile, a wide range of severity and disease durations. In all, it
describes a very benign picture for such a diverse group.
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